View Older Stories View More Recent Stories

Mar 31, 2017 08:27AM BioLineRx (BLRX) Prices 29.4M Offering at $0.85/ADS
Mar 31, 2017 08:25AM BioLineRx Prices $25 Million Underwritten Public Offering
Mar 30, 2017 04:18PM BioLineRx (BLRX) to Offer ADSs
Mar 30, 2017 04:01PM BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
Mar 27, 2017 09:15AM BioLineRx (BLRX) Says AGI-134 to be Featured at AACR
Mar 27, 2017 09:13AM BioLineRx's AGI-134 to be Presented at AACR 2017
Mar 23, 2017 08:00AM BioLineRx Reports Year End 2016 Financial Results
Mar 23, 2017 07:04AM BioLineRx (BLRX) Acquires Agalimmune
Mar 23, 2017 07:00AM BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline
Mar 20, 2017 07:17AM BioLineRx (BLRX) Reports Partial Results Data from Open-Label Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
Mar 20, 2017 07:00AM BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
Mar 16, 2017 10:00AM BioLineRx to Report Annual 2016 Results on March 23, 2017
Feb 7, 2017 07:00AM BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14
Jan 17, 2017 07:01AM BioLineRx (BLRX) Initiates Second Phase 2a Trial of BL-8040
Jan 17, 2017 07:00AM BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
Dec 5, 2016 07:08AM BioLineRx (BLRX) Presents Positive Phase 2a Correlative and Mechanism-of-Action Data for BL-8040 at ASH
Dec 5, 2016 07:00AM BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
Nov 22, 2016 08:00AM BioLineRx Reports Third Quarter 2016 Financial Results
Nov 21, 2016 07:06AM BioLineRx (BLRX) Enters In-Licensing Agreement for Anti-Inflammatory DES Treatment
Nov 21, 2016 07:00AM BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company
Nov 15, 2016 07:00AM BioLineRx to Report Third Quarter Results on November 22, 2016
Nov 3, 2016 09:09AM BioLineRx (BLRX) Reports Positive Phase 2a Correlative Data and Detailed Mechanism-of-Action Data for BL-8040
Nov 3, 2016 09:00AM BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
Oct 5, 2016 07:04AM BioLineRx (BLRX) BL-8040 Data Accepted for ASH Presentation
Oct 5, 2016 07:00AM BioLineRx Announces Acceptance of BL-8040 Abstracts for Oral and Poster Presentations at 58th American Society of Hematology (ASH) Annual Meeting
Sep 23, 2016 07:01AM BioLineRx (BLRX) Enters ESLD in-Licensing Agreement
Sep 23, 2016 07:00AM BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Sep 22, 2016 09:07AM BioLineRx (BLRX) Updates on Corp. Objectives; Plans Ramp-up of Several BL-8040 Combo Phase 1bs
Sep 22, 2016 09:00AM BioLineRx Ltd. Presents Corporate Objectives at Investor Breakfast Meeting in NY
Sep 20, 2016 07:03AM BioLineRx (BLRX) Commences BL-8040 Combo Phase 2a in Pancreatic Cancer
Sep 20, 2016 07:00AM BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
Sep 9, 2016 07:00AM BioLineRx Ltd. to Host Investor Breakfast Meeting September 22, 2016 in New York
Sep 8, 2016 07:01AM BioLineRx (BLRX) Announces Presentation of Positive BL-8040 Phase 2a Data in AML
Sep 8, 2016 07:00AM BioLineRx Presents Final Results from Phase 2a Trial for Relapsed/Refractory AML at SOHO Conference
Sep 7, 2016 07:03AM BioLineRx (BLRX), Genentech Enter Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab
Sep 7, 2016 07:00AM BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
Aug 29, 2016 07:00AM BioLineRx to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York
Aug 25, 2016 07:02AM BioLineRx (BLRX), I-Bridge Capital Form New JV in China
Aug 25, 2016 07:00AM BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China
Aug 11, 2016 06:47AM BioLineRx (BLRX) Appoints New CEO
Aug 11, 2016 06:45AM BioLineRx Names Philip A. Serlin as Chief Executive Officer
Aug 8, 2016 07:00AM BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
Aug 4, 2016 07:00AM BioLineRx to Report Second Quarter Results on August 11, 2016
Aug 1, 2016 07:00AM BioLineRx Announces In-licensing of Liver Fibrosis Project Under Strategic Collaboration
View More Recent Stories View Older Stories